GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » EV-to-EBIT
中文

Bolt Biotherapeutics (Bolt Biotherapeutics) EV-to-EBIT

: 0.52 (As of Today)
View and export this data going back to 2021. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bolt Biotherapeutics's Enterprise Value is $-39.65 Mil. Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-76.20 Mil. Therefore, Bolt Biotherapeutics's EV-to-EBIT for today is 0.52.

The historical rank and industry rank for Bolt Biotherapeutics's EV-to-EBIT or its related term are showing as below:

BOLT' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.08   Med: 0.58   Max: 1.17
Current: 0.52

During the past 6 years, the highest EV-to-EBIT of Bolt Biotherapeutics was 1.17. The lowest was -25.08. And the median was 0.58.

BOLT's EV-to-EBIT is ranked better than
77.03% of 444 companies
in the Biotechnology industry
Industry Median: 8.325 vs BOLT: 0.52

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bolt Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-39.28 Mil. Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-76.20 Mil. Bolt Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 193.97%.


Bolt Biotherapeutics EV-to-EBIT Historical Data

The historical data trend for Bolt Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -0.23 1.08 0.52

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.61 0.68 0.77 0.52

Competitive Comparison

For the Biotechnology subindustry, Bolt Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's EV-to-EBIT falls into.



Bolt Biotherapeutics EV-to-EBIT Calculation

Bolt Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-39.652/-76.196
=0.52

Bolt Biotherapeutics's current Enterprise Value is $-39.65 Mil.
Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (NAS:BOLT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bolt Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-76.196/-39.281648
=193.97 %

Bolt Biotherapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-39.28 Mil.
Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

By Value_Insider Value_Insider 11-01-2022